Euclidean Capital’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-82,234
| Closed | -$2.79M | – | 11 |
|
|
2025
Q4 | $2.79M | Hold |
82,234
| – | – | 0.75% | 8 |
|
|
2025
Q3 | $2.12M | Hold |
82,234
| – | – | 0.89% | 8 |
|
|
2025
Q2 | $658K | Sell |
82,234
-3
| -0% | -$23 | 0.22% | 9 |
|
|
2025
Q1 | $803K | Hold |
82,237
| – | – | 0.3% | 9 |
|
|
2024
Q4 | $1.04M | Hold |
82,237
| – | – | 0.14% | 10 |
|
|
2024
Q3 | $1.32M | Hold |
82,237
| – | – | 0.15% | 10 |
|
|
2024
Q2 | $2.01M | Hold |
82,237
| – | – | 0.25% | 9 |
|
|
2024
Q1 | $5.91M | Hold |
82,237
| – | – | 0.76% | 7 |
|
|
2023
Q4 | $16.3M | Hold |
82,237
| – | – | 1.84% | 4 |
|
|
2023
Q3 | $10.9M | Buy |
82,237
+10,833
| +15% | +$1.77M | 2.39% | 5 |
|
|
2023
Q2 | $10.7M | Buy |
71,404
+17,291
| +32% | +$2.69M | 2.75% | 7 |
|
|
2023
Q1 | $7.94M | Hold |
54,113
| – | – | 6.97% | 4 |
|
|
2022
Q4 | $8.57M | Hold |
54,113
| – | – | 8.02% | 5 |
|
|
2022
Q3 | $10.4M | Hold |
54,113
| – | – | 9.67% | 4 |
|
|
2022
Q2 | $7.9M | Hold |
54,113
| – | – | 6.72% | 6 |
|
|
2022
Q1 | $9.52M | Hold |
54,113
| – | – | 5.53% | 7 |
|
|
2021
Q4 | $15.9M | Sell |
54,113
-25,284
| -32% | -$6.76M | 9.04% | 5 |
|
|
2021
Q3 | $19.7M | Sell |
79,397
-12,578
| -14% | -$3.33M | 9.59% | 3 |
|
|
2021
Q2 | $23.4M | Hold |
91,975
| – | – | 7.59% | 4 |
|
|
2021
Q1 | $16.3M | Hold |
91,975
| – | – | 5.47% | 7 |
|
|
2020
Q4 | $14.5M | Buy |
+91,975
| New | +$20M | 3.08% | 8 |
|
Euclidean Capital's RAPT Position: Q1 2026 in Review
Euclidean Capital sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 82,234 shares — an estimated $2.79M sold.
Euclidean Capital first reported a position in RAPT in Q4 2020 and held it in 21 quarters. The position peaked at $23.4M in Q2 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Euclidean Capital reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Euclidean Capital sold 82,234 RAPT Therapeutics shares in Q1 2026, an estimated $2.79M.
- Euclidean Capital first reported a position in RAPT Therapeutics in Q4 2020 and held it in 21 quarters.
- Euclidean Capital's RAPT Therapeutics position peaked at $23.4M in Q2 2021.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Euclidean Capital's 13F filing for Q1 2026, filed 15 May 2026.